Proietti, Marco http://orcid.org/0000-0003-1452-2478
Vitolo, Marco
Harrison, Stephanie L.
Lane, Deirdre A.
Fauchier, Laurent
Marin, Francisco
Nabauer, Michael
Potpara, Tatjana S.
Dan, Gheorghe-Andrei
Boriani, Giuseppe
Lip, Gregory Y. H.
,
Funding for this research was provided by:
Abbott Vascular
Amgen Cardiovascular
AstraZeneca
Bayer
Boehringer Ingelheim
Boston Scientific Corporation
The Bristol Myers Squibb and Pfizer Alliance
The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company
Edwards Lifesciences
Gedeon Richter
Fondazione Internazionale Menarini
MSD-Merck & Co
Novartis Pharma
ResMed
Sanofi
Servier
Vifor Pharma
Università degli Studi di Milano
Article History
Received: 13 April 2021
Accepted: 20 July 2021
First Online: 27 August 2021
Declarations
:
: DL has received investigator-initiated educational grants from Bristol-Myers Squibb (BMS), has been a speaker for Boehringer Ingelheim and BMS/Pfizer and has consulted for BMS, Boehringer Ingelheim, and Daiichi-Sankyo. LF has been consultant or speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, Medtronic and Novartis; GB received small speaker’s fees from Medtronic, Boston, Boehringer Ingelheim and Bayer; GYHL has been consultant and speaker for BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo. No fees were received personally. All the disclosures happened outside the submitted work. All other authors have nothing to declare.